A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

Journal of Psychiatric Research

Volumn 36, Issue 1, 2002, Pages 7-18

  Peet, Malcolm ^a   Horrobin, David F ^b  

^a Swallownest Court ^*  (United Kingdom)

^b Laxdale Ltd   (United Kingdom)

Author keywords

Arachidonic acid; Clozapine; Ethyl eicosapentaenoate; Neuroleptics; Schizophrenia

Indexed keywords

ARACHIDONIC ACID; CLOZAPINE; ICOSAPENTAENOIC ACID ETHYL ESTER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CELL LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0036140127     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(01)00048-6     Document Type: Article

References (63)

1. A rating scale for drug-induced akathisia
2. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression
3. 5-Hydroxytryptamine2C receptor activation inhibits 5-hydroxytripamine1B-like receptor function via arachidonic acid metabolism
4. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART)
5. Effect of fish oil on heart rate variability in survivors of myocardial infarction: A double blind randomised controlled trial
6. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients
7. Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease
8. Placebo-controlled trial of glycine added to clozapine in schizophrenia
9. Purification and characterisation of phospholipase A2 from human epidermis
10. Increased serum phospholipase A2 activity in schizophrenia: A replication study
11. Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy
12. Membrane fatty acids, niacin flushing and clinical parameters
13. A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases
14. D-cycloserine added to clozapine for patients with schizophrenia
15. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
16. One hundred years of schizophrenia: A meta-analysis of the outcome literature
17. Fish consumption and major depression
18. Dietary polyunsaturated fatty acids and depression: When cholesterol does not satisfy
19. Schizophrenia as a prostaglandin deficiency disease
20. Abnormal membrane concentrations of 20 and 22-carbon essential fatty acids: A common link between risk factors and coronary and peripheral vascular disease?
21. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia
22. The effects of antipysychotic drugs on membrane phospholipids: A possible novel mechanism of action of clozapine
23. Depression and bipolar disorder: Relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, aging and osteoporosis: Possible candidate genes
24. The membrane hypothesis of schizophrenia
25. The niacin challenge test: Clinical manifestation of altered transmembrane signal transduction in schizophrenia?
26. Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells
27. The positive and negative syndrome scale (PANSS) for schizophrenia
28. Treatment of diabetic neuropathy with gamma-linolenic acid
29. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: An analysis of the Food and Drug Administration database
30. Single measurement of serum phospholipid fatty acid as a biomarker of specific fatty acid intake in middle-aged Japanese men
31. Omega 3 fatty acids and cardiovascular disease
32. Efficacy and extrapyramidal side-effects of the new antipsychotics olazapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotic and placebo. A meta-analysis of randomized controlled trials
33. An Elisa method for type IV cPLA2 in RBC: A potential marker for schizophrenia
34. Risperidone in the treatment of schizophrenia
35. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities
36. Schizophrenic symptoms and dietary intake of n-3 fatty acids
37. A new depression scale designed to be sensitive to change
38. Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus
39. New strategies for the treatment of schizophrenia: Omega-3 polyunsaturated fatty acids
40. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia
41. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics
42. Eicosapentaenoic acid (EPA) in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover
43. Eicosapentaenoic acid in treatment-resistant depression
44. Sustained remission of positive and negative symptoms of schizophrenia following dietary supplementation with polyunsaturated fatty acids
45. Laterality changes accompanying symptom remission in schizophrenia following treatment with eicosapentaenoic acid
46. Increased phospholipid breakdown in schizophrenia - Evidence for the involvement of a calcium-independent phospholipase A(2)
47. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication
48. A rating scale for extrapyramidal side effects
49. Omega 3 fatty acids in bipolar disorder - A preliminary double-blind, placebo-controlled trial
50. Serotonin, a potent modulator of arachidonic acid turnover, interaction with glutamatergic receptor in brain cortex
51. Clozapine increases apolipoprotein D expression in rodent brain: Towards a mechanism for neuroleptic pharmacotherapy
52. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
53. Substances affirmed as generally recognized as safe: Menhaden oil
54. Essential fatty acid and neuroleptic drug-associated tardive dyskinesia: Preliminary clinical observations
55. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia
56. Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonate-specific phospholipase A2
57. Niacin skin flush in schizophrenia: A preliminary report
58. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls
59. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures
60. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients
61. Membrane deficits in schizophrenia